175 related articles for article (PubMed ID: 20559888)
1. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
Adam Z; Krejcí M; Pour L; Feit J; Büchler T; Hájek R
Wien Klin Wochenschr; 2010 May; 122(9-10):311-4. PubMed ID: 20559888
[TBL] [Abstract][Full Text] [Related]
2. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
[TBL] [Abstract][Full Text] [Related]
3. [IgA pemphigus accompanying multiple myeloma].
Veselý K
Vnitr Lek; 2009 Oct; 55(10):915-6. PubMed ID: 19947233
[No Abstract] [Full Text] [Related]
4. Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Szturz P; Adam Z; Klincová M; Feit J; Krejčí M; Pour L; Zahradová L; Vašků V; Hájek R; Mayer J
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):517-20. PubMed ID: 21856265
[No Abstract] [Full Text] [Related]
5. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Howman R; Thakerer A; Pitman M; Ding N; Thompson PA; Khot A; Harrison SJ
Leuk Lymphoma; 2010 Dec; 51(12):2299-302. PubMed ID: 20929329
[No Abstract] [Full Text] [Related]
6. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
8. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Kropff M; Liebisch P; Knop S; Weisel K; Wand H; Gann CN; Berdel WE; Einsele H;
Ann Hematol; 2009 Nov; 88(11):1125-30. PubMed ID: 19274460
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
10. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
11. [Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone].
Okuno Y; Nishimura N; Nosaka K; Hata H; Mitsuya H
Rinsho Ketsueki; 2014 Apr; 55(4):461-5. PubMed ID: 24850459
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Fu W; Delasalle K; Wang J; Song S; Hou J; Alexanian R; Wang M
Am J Clin Oncol; 2012 Dec; 35(6):562-5. PubMed ID: 21694573
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Kumar SK; Flinn I; Noga SJ; Hari P; Rifkin R; Callander N; Bhandari M; Wolf JL; Gasparetto C; Krishnan A; Grosman D; Glass J; Sahovic EA; Shi H; Webb IJ; Richardson PG; Rajkumar SV
Leukemia; 2010 Jul; 24(7):1350-6. PubMed ID: 20508619
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB; Reece DE; Kukreti V; Mikhael JR; Chen C; Trudel S; Laumann K; Vohra H; Fonseca R; Bergsagel PL; Leis JF; Tiedemann R; Stewart AK
Br J Haematol; 2014 Nov; 167(4):563-5. PubMed ID: 24974945
[No Abstract] [Full Text] [Related]
17. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
18. A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist UH; Carlson K; Nahi H
Acta Haematol; 2013; 130(1):7-15. PubMed ID: 23363691
[TBL] [Abstract][Full Text] [Related]
19. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Reeder CB; Reece DE; Kukreti V; Chen C; Trudel S; Laumann K; Hentz J; Pirooz NA; Piza JG; Tiedemann R; Mikhael JR; Bergsagel PL; Leis JF; Fonseca R; Stewart AK
Blood; 2010 Apr; 115(16):3416-7. PubMed ID: 20413666
[No Abstract] [Full Text] [Related]
20. [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Szturz P; Jakubcová R; Adam Z; Klincová M; Krejcí M; Pour L; Zahradová L; Hájek R; Mayer J
Klin Onkol; 2011; 24(3):216-20. PubMed ID: 21717791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]